Literature DB >> 6142201

Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol.

D J Pennell, T O Nunan, M J O'Doherty, D N Croft.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6142201     DOI： 10.1016/s0140-6736(84)91807-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

1.  Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy.

Authors:  Roberto Leone; Lara Magro; Ugo Moretti; Paola Cutroneo; Martina Moschini; Domenico Motola; Marco Tuccori; Anita Conforti
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

2.  Adverse drug reactions leading to hospital admission.

Authors:  L Ibáñez; J R Laporte; X Carné
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 3.  Selecting appropriate antihypertensive drug dosages.

Authors:  G D Johnston
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 4.  Fosinopril. Clinical pharmacokinetics and clinical potential.

Authors:  H Shionoiri; M Naruse; K Minamisawa; S Ueda; H Himeno; S Hiroto; I Takasaki
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

5.  Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study.

Authors:  Chio Yokose; Na Lu; Hui Xie; Lingyi Li; Yufei Zheng; Natalie McCormick; Sharan K Rai; J Antonio Aviña-Zubieta; Hyon K Choi
Journal:  CMAJ       Date:  2019-09-30       Impact factor: 8.262

Review 6.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 7.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

8.  Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.

Authors:  Alexandra E Rätz Bravo; Lydia Tchambaz; Anita Krähenbühl-Melcher; Lorenzo Hess; Raymond G Schlienger; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 9.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

10.  Captopril: 4 years of post marketing surveillance of all patients in New Zealand.

Authors:  I R Edwards; D M Coulter; D M Beasley; D MacIntosh
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.